Immunotec Inc. said its normalized net income for the fiscal second quarter ended April 30 was C$267,070, a fall of 61.4% from C$692,240 in the year-earlier period.
Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.
The normalized profit margin fell to 1.3% from 3.6% in the year-earlier period.
Total revenue grew year over year to C$20.0 million from C$19.1 million, and total operating expenses climbed 5.1% from the prior-year period to C$18.7 million from C$17.8 million.
Reported net income decreased 53.2% year over year to C$323,180, or 0 cents per share, from C$690,680, or 1 cents per share.
